Trials / Completed
CompletedNCT05768113
LAEH Formulation Nasal Spray to Reduce Viral Load
A Randomized, Double-blind, Multi-center Study to Evaluate the Efficacy and Safety of Ethyl Lauroyl Arginate Hydrochloride (LAEH) Formulation Versus a Matching Placebo Formulation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- Salvacion USA Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The Covixyl-V LAEH Nasal Spray's safety and efficay is clinically tested for use in subjects with COVID-19 infection. A randomized, double-blind, multi-center study is conducted to evaluate the efficacy and safety of ethyl lauroyl arginate hydrochloride (LAEH) formulation versus a matching placebo formulation administered as a nasal spray to reduce viral load from nasal area of subjects with coronavirus disease 2019 (COVID-19).
Detailed description
The primary endpoint for this study was the comparison of change in viral load in RT-PCR Test. Proportion of COVID-19 infection-free subjects between the two treatment arms was followed.
Conditions
Timeline
- Start date
- 2021-05-29
- Primary completion
- 2021-10-04
- Completion
- 2022-01-06
- First posted
- 2023-03-14
- Last updated
- 2023-03-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05768113. Inclusion in this directory is not an endorsement.